Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2487-2498

  Chen, Min Bin ^a   Wu, Xiao Yang ^a   Tao, Guo Qing ^b   Liu, Chao Ying ^b   Chen, Jian ^a   Wang, Li Qiang ^a   Lu, Pei Hua ^b  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

apoptosis; colorectal cancer; curcumin; perifosine; signal transduction

Indexed keywords

CERAMIDE; CURCUMIN; CYCLIN D1; I KAPPA B ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PERIFOSINE; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIZATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CACO-2 CELLS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CERAMIDES; COLORECTAL NEOPLASMS; CURCUMIN; CYCLIN D1; DOWN-REGULATION; DRUG SYNERGISM; ENDOPLASMIC RETICULUM; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; I-KAPPA B PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, SCID; NF-KAPPA B; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867044935     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27548     Document Type: Article

References (47)

1. Chen A, Xu J, Johnson AC,. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006; 25: 278-87.
2. Mohandas KM, Desai DC,. Epidemiology of digestive tract cancers in India. V. Large and small bowel. Ind J Gastroenterol 1999; 18: 118-21.
3. Rajasekaran SA,. Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol 2011; 2: 1-14.
4. Taylor RA, Leonard MC,. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev 2011; 16: 152-6.
5. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME,. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000; 275: 10405-12.
6. Campbell FC, Collett GP,. Chemopreventive properties of curcumin. Future Oncol 2005; 1: 405-14.
7. Goel A, Boland CR, Chauhan DP,. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001; 172: 111-8.
8. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK,. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007; 13: 3423-30.
9. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, Majumdar AP,. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 2008; 122: 267-73.
10. Du B, Jiang L, Xia Q, Zhong L,. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 2006; 52: 23-8.
11. Howells LM, Mitra A, Manson MM,. Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines. Int J Cancer 2007; 121: 175-83.
12. Harigaya K, Fujita M,. Dimerization structures of metallic and semiconducting fullerene tubules. Phys Rev B Condens Matter 1993; 47: 16563-9.
13. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J,. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 1997; 33: 442-6.
14. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound- rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010; 9: 963-75.
15. van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont AM, ten Hagen TL, Verheij M, Koning GA,. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J 2011; 25: 280-9.
16. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK,. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-103.
17. Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ,. Alkyl- lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 2001; 49: 415-9.
18. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM,. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008; 22: 1106-16.
19. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC,. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-62.
20. Li X, Luwor R, Lu Y, Liang K, Fan Z,. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 2006; 25: 525-35.
21. Fu L, Lin YD, Elrod HA, Yue P, Oh Y, Li B, Tao H, Chen GZ, Shin DM, Khuri FR, Sun SY,. c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Mol Cancer 2010; 9: 315.
22. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM,. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 2002; 62: 1401-9.
23. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S,. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65: 2422-32.
24. Sun H, Yu T, Li J,. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett 2011; 310: 118-28.
25. Chen MB, Wu XY, Gu JH, Guo QT, Shen WX, Lu PH,. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 2011; 60: 311-22.
26. Chen MB, Shen WX, Yang Y, Wu XY, Gu JH, Lu PH,. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Physiol 2011; 226: 1915-25.
27. Moussavi M, Assi K, Gomez-Munoz A, Salh B,. Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 2006; 27: 1636-44.
28. Majumdar AP, Banerjee S, Nautiyal J, Patel BB, Patel V, Du J, Yu Y, Elliott AA, Levi E, Sarkar FH,. Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr Cancer 2009; 61: 544-53.
29. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M,. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14: 167-73.
30. Moragoda L, Jaszewski R, Majumdar AP,. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 2001; 21: 873-8.
31. Aggarwal BB, Kumar A, Bharti AC,. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-98.
32. Thangapazham RL, Sharma A, Maheshwari RK,. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 2006; 8: E443-9.
33. Grandage VL, Gale RE, Linch DC, Khwaja A,. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005; 19: 586-94.
34. Salminen A, Kaarniranta K,. Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal 2009; 22: 573-7.
35. Jin S, Pang RP, Shen JN, Huang G, Wang J, Zhou JG,. Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis 2007; 12: 1317-26.
36. Yu T, Li J, Sun H,. C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro. Cancer Chemother Pharmacol 2010; 66: 999-1003.
37. Merrill AH, Jr., van Echten G, Wang E, Sandhoff K,. Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem 1993; 268: 27299-306.
38. Bakhshi J, Weinstein L, Poksay KS, Nishinaga B, Bredesen DE, Rao RV,. Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. Apoptosis 2008; 13: 904-14.
39. Pae HO, Jeong SO, Jeong GS, Kim KM, Kim HS, Kim SA, Kim YC, Kang SD, Kim BN, Chung HT,. Curcumin induces pro-apoptotic endoplasmic reticulum stress in human leukemia HL-60 cells. Biochem Biophys Res Commun 2007; 353: 1040-5.
40. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, Yuan J,. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005; 307: 935-9.
41. Patel BB, Majumdar AP,. Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer 2009; 61: 842-6.
42. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y, Majumdar AP,. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 2010; 30: 319-25.
43. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP,. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2009; 2: 321-8.
44. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP,. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90: 1011-5.
45. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB,. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-5.
46. Romashkova JA, Makarov SS,. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
47. Chen YR, Tan TH,. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998; 17: 173-8.